About Remicade (infliximab) Dosing

This information provides context for the Remicade (infliximab) Dosing Calculator. Remicade is a chimeric monoclonal antibody administered via intravenous infusion for various autoimmune and inflammatory conditions. Its dosing is highly individualized, based primarily on patient weight (in kilograms) and the specific clinical indication being treated. The treatment regimen is typically divided into two phases: an initial induction phase to establish therapeutic levels, followed by a long-term maintenance phase to sustain clinical response.

Accurate dose calculation is critical for ensuring efficacy and safety. This content is for educational purposes and should not replace clinical judgment or the official prescribing information.

Understanding the Calculator Outputs

The calculator provides four key outputs to guide the preparation and administration of an infliximab infusion:

• Calculated Dose (mg): This is the precise dose required for the patient, calculated as: (Patient Weight in kg) × (Dose in mg/kg).
• Vials Required (100 mg): Remicade is supplied in 100 mg vials. This value indicates the total number of vials needed to prepare the calculated dose. Since partial vials cannot be used, this number is always rounded up to the next whole number.
• Total Drug Prepared (mg): This reflects the total amount of infliximab available from the required vials (e.g., 3 vials = 300 mg). This will often be higher than the calculated dose due to the vial rounding.
• Volume to Withdraw (mL): After reconstituting each 100 mg vial with 10 mL of Sterile Water for Injection (resulting in a 10 mg/mL concentration), this is the total volume needed to be withdrawn from all reconstituted vials to obtain the exact calculated dose.

How to Use the Calculator

To determine the correct dosing and preparation parameters, follow these steps:

1. Enter Patient Weight: Input the patient's weight. You can toggle the unit between kilograms (kg) and pounds (lbs); the tool will automatically convert the value to kg for the calculation.
2. Select Clinical Indication: Choose the appropriate approved indication from the dropdown menu, as dosing differs between conditions like Crohn's Disease, Rheumatoid Arthritis, and Plaque Psoriasis.
3. Choose Dosing Phase: Select either "Induction" for the initial loading doses or "Maintenance" for subsequent, regularly scheduled infusions. The standard mg/kg dose will update automatically.
4. Adjust Dose (if necessary): The standard dose is pre-filled but the field is editable. A clinician may adjust the mg/kg value based on patient response or clinical guidelines (e.g., escalating from 5 mg/kg to 10 mg/kg).

Dosing Overview

Remicade dosing is weight-based and indication-specific. A typical treatment course begins with an induction phase followed by a maintenance schedule.

• Induction Phase: Patients receive initial infusions, commonly at Week 0, Week 2, and Week 6, to rapidly achieve therapeutic drug levels and control disease activity.
• Maintenance Phase: After induction, patients move to a regular infusion schedule to maintain remission. The frequency varies by indication, typically every 6 or 8 weeks.
• Dose Adjustments: For some indications, the dose may be increased (e.g., from 5 mg/kg to 10 mg/kg) or the interval shortened (e.g., from every 8 weeks to every 4 weeks) in patients who lose response.

Switching and Discontinuation

Decisions regarding switching to or from Remicade (or its biosimilars) and other biologic agents should be made by a qualified healthcare professional. This involves careful consideration of the patient's disease history, previous treatments, and current clinical status. Discontinuation of therapy should also be medically supervised, as it may lead to a relapse of the underlying condition.

Missed Dose Protocol

If a patient misses a scheduled infusion, they should contact their healthcare provider immediately to reschedule. The provider will determine the best course of action for resuming the dosing schedule. Patients should be advised not to wait for the next regularly scheduled appointment without medical consultation.

Safety Alerts

Remicade (infliximab) has a Boxed Warning regarding serious risks. Healthcare professionals must be aware of the following:

• Serious Infections: Patients treated with Remicade are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections, and other opportunistic infections. Patients should be tested for latent TB before starting Remicade.
• Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Remicade.

Frequently Asked Questions (FAQ)

Why is the "Dose per Kilogram" field editable?
The field is pre-filled with the standard dose for the selected indication and phase but remains editable to allow clinicians to make necessary adjustments based on patient response, such as dose escalation for loss of response, as permitted by the prescribing information.

How does the calculator convert between kilograms (kg) and pounds (lbs)?
The tool uses the standard conversion factor of 1 kg = 2.20462 lbs. When you enter a value and toggle the unit, it performs this conversion automatically to ensure the underlying calculation is always based on kilograms.

What is the difference between "Calculated Dose" and "Total Drug Prepared"?
"Calculated Dose" is the precise amount the patient needs based on their weight. "Total Drug Prepared" is the full amount of medication available from the whole vials you must use, which is often more than the calculated dose.

Why are vials always rounded up?
Pharmaceutical vials are for single use and cannot be partially used for one patient and saved for another. Therefore, you must use enough whole vials to draw the required dose, necessitating rounding up.

Can this calculator be used for infliximab biosimilars (e.g., Inflectra, Renflexis)?
While biosimilars have the same dosing and administration guidelines as the reference product (Remicade), you must always refer to the specific prescribing information for the biosimilar being used.

What concentration is assumed for the "Volume to Withdraw" calculation?
The calculation assumes each 100 mg vial of infliximab is reconstituted with 10 mL of Sterile Water for Injection, USP, yielding a final concentration of 10 mg/mL.

Can this tool be used for patients under 6 years of age?
No. The calculator's indications are based on Remicade's approval for adults and pediatric patients aged 6 years and older for specific conditions like Crohn's Disease and Ulcerative Colitis.

What does the "Recommended Dosing Schedule" information refer to?
This text, which appears with the results, describes the standard timing of infusions for the selected phase (e.g., "Infusions at Week 0, Week 2, and Week 6" for induction), providing context for the single-dose calculation.

References

• REMICADE® (infliximab) Prescribing Information. U.S. Food and Drug Administration.
• Janssen CarePath for Remicade (HCP Portal). Janssen Biotech, Inc.
• Remicade European public assessment report (EPAR). European Medicines Agency.
• ACG Clinical Guideline: Management of Crohn's Disease in Adults. American Journal of Gastroenterology.